|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on September 12, 2002; DOI 10.1182/blood-2002-04-1003.
IMMUNOBIOLOGY
From the Arthritis and Immunology Program, Oklahoma
Medical Research Foundation, Oklahoma City; W. K. Warren Medical
Research Institute, Oklahoma City; Department of Veterans Affairs
Medical Center and the Department of Medicine, University of Oklahoma
Health Sciences Center, Oklahoma City.
Systemic lupus erythematosus (SLE) is a complicated
autoimmune disease with a definite genetic predisposition.
Thrombocytopenia predicts severe disease and death in SLE, making the
identification of the related genetic risk factors especially
important. We selected the 38 pedigrees that had an SLE patient with
thrombocytopenia (platelets, < 10 × 109/L
[< 100 000/µL]) from a collection of 184 pedigrees multiplex for
SLE. Linkages were established at 1q22-23 (maximum logarithm of
odds [lodmax] = 3.71) in the 38 pedigrees and
at 11p13 (lodmax = 5.72) in the 13 African American
pedigrees. Nephritis, serositis, neuropsychiatric involvement,
autoimmune hemolytic anemia, anti-double-stranded DNA, and
antiphospholipid antibody were associated with thrombocytopenia. Other
results show that SLE is more severe in the families with a
thrombocytopenic SLE patient, whether or not thrombocytopenia in an
individual patient is considered. These results are consistent with
thrombocytopenia being a component of a severe familial form of SLE and
with genes at 1q22-23 and 11p13 contributing to this severe phenotype
and to the subsequent high mortality associated with thrombocytopenia
in SLE.
(Blood. 2003;101:992-997) Systemic lupus erythematosus (SLE) is a clinically
and immunologically complex disease, which can affect any organ system. The disease may be mild, or severe and life threatening. This variability is reflected in the classification system proposed by the
American College of Rheumatology (ACR)1 in which patients with SLE may fulfill any 4 of 11 criteria. The presence of antinuclear antibodies (ANA) is the most sensitive of these criteria and is present
in virtually all patients.
SLE also has complicated genetics. The disease tends to occur within
families, but without a clear pattern of inheritance (reviewed in
Sestak et al2). Familial aggregation has been reported as
2% to 5% among siblings of patients with SLE, whereas concordance
among identical twins may be no more than 25%.3,4 Several
genome-wide scans suggest that many genes are involved in the
predisposition to SLE.5-10
Patients with SLE can have multiple hematologic abnormalities,
including thrombocytopenia (< 10 × 109/L
[< 100 000/µL]). Serious organ involvement in lupus is
associated with thrombocytopenia. This involvement includes
neuropsychiatric manifestations,11 hemolytic
anemia,12,13 the antiphospholipid syndrome,14
renal disease,13,15 and, most ominously,
death.14-20 SLE patients with thrombocytopenia rarely die
of bleeding complications. Nevertheless, thrombocytopenia forecasts a
poor prognosis for SLE.14-20 Two large studies of
SLE16,17 have shown that thrombocytopenia was the only, or
virtually the only, independent risk factor for mortality in SLE. These
studies involved European American, Hispanic, and African
American patients with SLE.16,17 In addition,
studies from Chile, Canada, and Southern China show poorer survival in SLE patients with thrombocytopenia. Although a few studies show no
influence of thrombocytopenia on survival,13,21 most do show an effect with the relative risk of death during the period of
follow-up being increased from 1.5- to 45-fold.14-18,20
Clearly, thrombocytopenia is an important prognostic indicator for
survival in lupus.
We used the presence of thrombocytopenia to stratify SLE families
in an effort to increase homogeneity for genetic linkage studies.
Families with thrombocytopenia in at least one SLE patient, taken from
the Oklahoma collection of familial SLE,6,22,23 show
sufficiently strong evidence to establish genetic linkages at
chromosome 11p13 and 1q22-23. Other data demonstrate that
thrombocytopenia identifies SLE families with a severe phenotype of the illness.
Patients and pedigrees
Serologic evaluation
Genotyping Genomic DNA was isolated from peripheral blood mononuclear cells, buccal cell swabs, or lymphoblastoid cell lines by using conventional methods as previously described.22 A total of 307 microsatellite markers were typed from the Version 8 Weber screening set (http://research.marshfieldclinic.org/genetics/sets/Set8ScreenFrames.htm). Polymerase chain reactions were performed as previously described.22 Amplified fragments were detected by using 6% polyacrylamide gels electrophoresed on automated LiCor (Lincoln, NE) Model 4000 DNA sequencers. Gel images were collected by using Base ImagIR software, version 4.0, and alleles were determined by using Gene ImagIR, version 3.52. Twenty-nine pedigrees were initially genotyped by the Mammalian Genotyping Center in Marshfield, WI (http://research.marshfieldclinic.org/genetics/), using a fluorescent-based detection system.Linkage analysis Prior to any linkage analysis, sibling, half-sibling, and parent-offspring relationships were confirmed by using the statistics generated by RELTEST, a feature of the S.A.G.E. 4.0 package, version Beta 3.28,29 For all linkage analyses, the pedigrees were analyzed together and as subsets containing only African American or European American pedigrees.Maximum-likelihood model-based linkage analysis Two-point maximum logarithm of odds (lod) scores were calculated by using FASTLINK, version 4.1P, and the ANALYZE package.30-32 Lod scores were generated for each pedigree by using recombination fractions in increments of 0.05 from 0 (complete linkage) to 0.50 (no linkage). The final maximum likelihood estimate for each microsatellite marker was produced by summing each recombination fraction across all of the pedigrees. Six inheritance models were used for screening analysis as described elsewhere.6 SLE affects men and women at a different rate. We incorporated this difference into the models by using one penetrance function for men and another for women. For each marker, allele frequencies were estimated by allele counting using founders. Screening lod scores were calculated by using the MLINK subroutine of the ANALYZE package.Model-free linkage analysis Multipoint linkage analysis on concordant and discordant sibling pairs was performed at 2-cM increments for all 22 autosomes by using the new Haseman-Elston regression technique used by SIBPAL2, a subtest of the S.A.G.E 4.0 package, version Beta 3.29,33 The algorithm regresses the identity by descent sharing values against the mean corrected cross product of the sib-pair trait difference. In addition, we performed a multipoint affected-relative pairs (ARPs) analysis by using LODPAL, also a subroutine of the S.A.G.E. 4.0 Beta, version 7. This analysis models covariance of all affected relative pairs as a function of marker allele-sharing identical by descent using the conditional logistic model proposed by Olson34 and Goddard et al.35
There were a total of 387 patients with SLE in the 184 families evaluated. Of these, 116 families and 233 patients with SLE were of European ancestry, whereas 63 families and 133 patients with SLE were of sub-Saharan African ancestry. A total of 47 (12.1%) of the 387 patients with SLE had definite thrombocytopenia as defined by the criteria (platelet count, < 10 × 109/L [< 100 000/mm3] without another cause), a frequency that did not vary among racial groups. Twenty-seven of those with thrombocytopenia were European American; among the African American patients, 15 patients from 14 families had thrombocytopenia, of which 13 pedigrees were useful for linkage. Five patients with thrombocytopenic SLE were from 5 different Hispanic families. We examined the clinical characteristics of the SLE patients with
thrombocytopenia. There were 43 women and 4 (8.5%) men, whereas 9.3% of the total SLE patient population was male.
The average age of onset of SLE was 24.1 years (standard
deviation = 8.3), which did not differ from the SLE patients without
thrombocytopenia (not shown). The average lowest platelet count was
2.4 × 109/L (24 000) with a range of 1 to
90 × 109/L (1000-90 000/mm3). Among the
families that had a patient with thrombocytopenic SLE, about one half
constituted a sibling pair, whereas in the other families the
relationships of the patients with SLE were more complicated (Figure
1). The family structures of the African American families with thrombocytopenic SLE that were useful for linkage are given in Figure 1.
Thrombocytopenia was associated with other manifestations of SLE within
this cohort of patients (Tables 1 and 2), including autoimmune
hemolytic anemia and lupus renal disease as defined by the ACR
criteria.1,24 The relationship between thrombocytopenia and hemolytic anemia was present when those of European or African ancestry were evaluated separately (Table
1). Neuropsychiatric disease is also
associated with thrombocytopenia in SLE (Table 2), most strikingly among the European
Americans. Serositis, arthritis, and the cutaneous criteria for SLE
classification (malar rash, discoid rash, photosensitivity, and oral
ulcers) were not associated with thrombocytopenia (data not shown).
Anti-dsDNA and antiphospholipid antibodies were found more often in patients with thrombocytopenic SLE (Table 2), whereas antinuclear antibodies, anti-Sm, and anti-nRNP were not (data not shown). In addition, among black patients anti-Ro (or Sjögren syndrome A [SS-A]) was found much more commonly in those with thrombocytopenia of whom 9 (60%) of 15 had anti-Ro. Meanwhile, only 24 (20.5%) of the remaining 117 African Americans had anti-Ro (chi-squared test = 11.1, P < .001, odds ratio = 5.8; Table 2). Of course, each individual with SLE is related to at least one other subject with SLE in these families. So, the variables are not completely independent. However, analyses of all these clinical and laboratory manifestations of SLE using a single patient from each family showed similar results (data not shown). We next tested whether or not thrombocytopenia in individuals or within families of the Oklahoma pedigree collection may identify a severe lupus phenotype, consisting of multiple thrombocytopenia-associated characteristics. Such a phenotype was arbitrarily defined as 2 or more of the autoantibodies (anti-ds DNA, anti-Ro, or antiphospholipid antibody) and 2 or more of the clinical manifestations that are associated with thrombocytopenia (serositis, nephritis, neuropsychiatric disease, and hemolytic anemia). Seventeen (36.2%) of the 47 patients with thrombocytopenic SLE had the phenotype as defined, whereas only 53 (15.5%) of 340 patients with nonthrombocytopenic SLE did so (odds ratio = 2.85, chi-squared test = 15.3, P < .0001). Provocatively, this phenotype was of nearly identical frequency in SLE patients with thrombocytopenia and their nonthrombocytopenic SLE-affected family members (28 [31.8%] of 88 versus 17 [36.1%] of 47, chi-squared test = 0.46, P > .05). Moreover, the patients with nonthrombocytopenic SLE in the thrombocytopenia pedigrees have a much higher frequency of this severe phenotype than do patients with SLE in the pedigrees with no thrombocytopenia (45 [33.3%] of 135 versus 25 [9.9%], of 252, odds ratio = 4.5, chi-squared test = 23.8, P < .000 001). Thrombocytopenia in a patient with SLE, therefore, is associated with more severe disease in her or his relatives who also have lupus. A severe lupus phenotype is, therefore, not so much a characteristic of thrombocytopenic lupus, but instead a characteristic of patients with lupus from families identified by having one patient with thrombocytopenic lupus. Familial aggregation of the severe phenotype in these pedigrees predicts that the genetic linkages found in the pedigrees containing a SLE patient with thrombocytopenia will be associated with a more severe form of lupus. Patients with these SLE susceptibility genes would be expected to have increased morbidity and mortality from SLE. Genetic linkage of familial lupus among families with
thrombocytopenia as a manifestation of lupus was assessed by
using 6 screening models of inheritance (Table
3). We used the microsatellite genotyping data to screen with 2-point lod scores by using a maximum likelihood model-based linkage analysis (Table
4). The most interesting screening result
demonstrates a lod score of 3.803 for marker D11s1392 on chromosome
11p13 among families of African American heritage (Table 3). This lod
score exceeds the accepted threshold for established
linkage.36 The best screening model for this effect is
autosomal dominant with a penetrance of 97% in women and 42% in men.
We next optimized this model based on penetrance for the 2 sexes and
frequency of the disease allele (Figure
2). The best model assumed that a rare,
dominantly inherited factor segregated with the affected individuals
(male or female). In this model, the disease allele frequency was
pD = 0.001, where the 3 penetrances for men were
Fdd, = 0.0, FDd = 0.39, and
FDD = 0.39, and the 3 penetrances for women were
Fdd = 0.0, Fdd = 0.99, and
FDD = 0.99. The estimated prevalence of disease based on
this model was 0.14%, which is very similar to the observed population
prevalence of SLE. The maximum 2-point lod score of 4.89 was obtained
with marker D11s1392 under complete homogeneity among African American
families. The peak multipoint lod score of 5.72 under a dominant model
was obtained at 41.7 cM between markers A34E8 and D11S1392 (Figure 2).
The maximum nonparametric linkage score of 2.12 was obtained at the
same position (P = .01) (Figure 2). Low informativity
(0.34-0.45) is likely a major contributor to the low nonparametric
linkage score.
A model-free, multipoint linkage analysis of identity by descent
sharing among related SLE-affected pairs (SIBPAL2) produced findings of
interest on chromosomes 2 and 5 (Figure
3), both meeting the threshold for a
suggestive linkage (P
We have examined the clinical associations and the genetics of thrombocytopenia in a relatively large collection of families multiplex for systemic lupus erythematosus. The data support thrombocytopenia-identified families tend to have a more severe lupus phenotype. In addition, new previously undetected linkages are found, also consistent with the possibility that thrombocytopenia in SLE identifies a group of pedigrees with increased genetic homogeneity. This result also supports the possibility that some of the heterogeneity of lupus clinical expression has a genetic origin. Thrombocytopenia, a part of the widely accepted classification criteria, as proposed by the ACR,1,24 is one of the most interesting expressions of SLE because of its association with mortality and other serious clinical manifestations.14-21 Low platelets occur in 10% to 25% of patients with SLE.15,17 Thrombocytopenia can be categorized in 2 subgroups. This complication may occur acutely in association with severe, multisystem SLE disease flares, or it may be a chronic condition that is present even when the disease is otherwise quiescent.13 Reveille et al16 first reported an association of mortality and thrombocytopenia among patients with lupus.16 In a multivariate analysis, thrombocytopenia was the only independent risk factor for death among the 389 patients with SLE followed for a mean of 8.8 years. Others have demonstrated similar findings.14-20 Other features of patients with SLE such as age of onset, presence of antiphospholipid antibody, renal disease, steroid dose, sex, and race have been found to be associated with risk of death in some studies. Nonetheless, even though patients with SLE rarely die of bleeding complications, thrombocytopenia is the clinical feature most consistently found to be associated with mortality in SLE. Thrombocytopenia also has several other reported associations with other manifestations of SLE. For instance, 25% of SLE patients with neuropsychiatric manifestations had thrombocytopenia, whereas only 7% of nonneuropsychiatric patients did so.11 Autoimmune hemolytic anemia and thrombocytopenia have been found to be highly associated.12,15 Patients with one or both of these manifestations were also found to have more renal disease.12 Renal disease has been associated with thrombocytopenia in other studies.15 In the present study of 387 patients with SLE, we found that thrombocytopenia was associated with serositis, neuropsychiatric disease, renal disease, and autoimmune hemolytic anemia (Table 2). In addition to these clinical associations, we also found that thrombocytopenia was more common among patients with antiphospholipid antibody, anti-dsDNA or, in African Americans, anti-Ro (Table 3). A severe lupus phenotype consisting of at least 2 of the thrombocytopenia-associated clinical manifestations and 2 of the associated autoantibodies was much more common among patients with thrombocytopenia and their affected family members than among patients from families without thrombocytopenia. Thus, thrombocytopenia identifies not just patients, but also families, with a severe lupus phenotype, despite thrombocytopenia not often being a familial trait among patients with SLE. Because thrombocytopenia identifies a severe subset of lupus patients and families, we hypothesized that this group might have more homogeneous genetics compared with lupus patients in general. This appears to be the case. By performing a lod score analysis and a related-affected pair analysis on the lupus families with thrombocytopenia as a manifestation, we have established genetic linkage not previously identified.6,22 On chromosome 11 at marker D11s1392 a lod score of 4.89 and a maximum multipoint lod score of 5.7 were obtained in only 13 African American SLE families (Figure 2). Using SLE alone as the phenotype, we previously did not establish linkage at this genetic interval (lod = 1.87).6 There are a number of interesting candidate genes near this marker, including CD44 that is located 0.5 cM from D11s1392. We studied a microsatellite trinucleotide repeat within this gene and confirmed linkage with a screening lod score of 2.7. Thus, this new marker confirms linkage in this region. We also examined several single nucleotide polymorphisms within this gene and did not find association with lupus in the 13 African American families. Thus, these preliminary data imply that the gene responsible for the effect seen at this chromosomal location is not CD44.37 The genomic map for this region of chromosome 11 is incomplete, but there are several other genes of interest that are mapped to 11p13. Included among these are CD59, RAG-1, and the Wilms tumor suppressor WT1, all of which are involved in immune cell development. Also, present within the genetic interval are the fas-interacting serine/threonine kinase (FIST/HIPK3) as well as tumor necrosis factor (TNF) receptor-associated factor 6. We have also established linkage at 1q22-23. This region is very near other established linkages on chromosome 16 and may reflect the effect of the previously detected gene(s). We have found evidence suggestive of linkage on chromosome 2, with the greatest effect at D2s1384. Similar to the chromosome 11 effect, no important effect was seen at this position when performing a genome-wide scan of all the pedigrees.6 Icelandic pedigrees collected in Uppsala, Sweden, show a linkage effect at 2q37.8 This is approximately 50 cM away from the 2q34 linkage described herein, which is probably too distant to be the same genetic effect. Affected pair analysis also supported an effect on chromosome 5 that exceeded the threshold for a suggestive linkage but not the threshold for established linkage (Tables 4 and 5). Another result also supports the hypothesis that this region of chromosome 5 contains a gene important for lupus. Gray-McGuire et al22 used a revised multipoint Haseman-Elston regression technique along with a conditional logistic regression model-building technique. This technique found a novel linkage to chromosome 4p16-15.2 that is in epistasis with the same 5p15 marker reported herein. Thus, multiple techniques of analysis support the findings of linkage
of chromosomes 1, 2, 5, and 11 that are herein reported in SLE families
in which at least one patient had thrombocytopenia. These are genetic
linkages to lupus as a phenotype. Although their relationship to
thrombocytopenia (or other associated findings) must be important, they
are not necessarily direct nor are they revealed by this study. In any
case, the success of this study provides another example of clinical
features providing a stratification strategy for genetic analysis, one
that increases statistical power through presumed increased genetic
homogeneity. Clearly, stratification by clinical factors was critical
for identification of the BCR1 gene38 as well
as the gene for familial Mediterranean fever.39 We have
also used this approach in studying SLE families with
vitiligo40 or hemolytic anemia41 with
resulting identification of genetic linkages distinct from the ones
identified herein. For the 11p13 linkage, stratification by race and
the presence of low platelets has produced one of the largest genetic
effects reported to date in lupus (lodmax = 5.7). These
data demonstrate the capacity of disease clinical manifestations to be
informative for the genetics of SLE. Of course, stratification of our
cohort may also lead to problems. By reducing the number of families, the potential for The genetics of human SLE are obviously extremely complicated, which is likely the result of heterogeneity, low penetrance, and simultaneously operating protective genetic effects, among other impediments. Genes related to thrombocytopenia in lupus may also be related to clinically severe disease and early demise.11-20 If the pathology of the severe, deadly forms of this disease is ever to be understood and if genetic elucidation will generate new therapeutic options, then these are the genetic effects that require our most concentrated attention.
We thank the study participants for their help with this research effort. Some of the results presented herein were obtained with S.A.G.E. (RR03 655). Ninety pedigrees (cohorts A, B, and C) were obtained from the Lupus Multiplex Registry and Repository (AR-1-2253).
Submitted April 19, 2002; accepted September 2, 2002.
Prepublished online as Blood First Edition Paper, September 12, 2002; DOI 10.1182/blood-2002-04-1003.
Supported by the National Institutes of Health (AR-1-2253, AI24717, AR42460, AR45231, AI31584, and RR15577).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: R. Hal Scofield, 825 NE 13th St, Oklahoma City, OK 73104; e-mail: hal-scofield{at}omrf.ouhsc.edu.
1. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-1277[Medline] [Order article via Infotrieve]. 2. Sestak AL, Shaver TS, Moser KL, et al. Familial aggregation of lupus and autoimmunity in an unusual multiplex pedigree. J Rheumatol. 1999;26:1495-1499[Medline] [Order article via Infotrieve]. 3. Hochberg MC. The application of genetic epidemiology to systemic lupus erythematosus. J Rheumatol. 1987;14:867-869[Medline] [Order article via Infotrieve]. 4. Deapen D, Escalante A, Weinrib L, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum. 1992;35:311-318[Medline] [Order article via Infotrieve]. 5. Harley JB, Sheldon P, Neas B, et al. Systemic lupus erythematosus: considerations for a genetic approach. J Invest Dermatol. 1994;103:144S-149S[CrossRef][Medline] [Order article via Infotrieve].
6.
Moser KL, Neas BR, Salmon JE, et al.
Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees.
Proc Natl Acad Sci U S A.
1998;95:14869-14874
7.
Gaffney PM, Kearns GM, Shark KB, et al.
A genome-wide search for susceptibility genes in human systemic lupus erythematosus sib-pair families.
Proc Natl Acad Sci U S A.
1998;95:14875-14879 8. Lindqvist AKB, Steinsson K, Johanneson B, et al. A susceptibility locus for human systemic lupus erythematosus (hSLE1) on chromosome 2q. J Autoimmunity. 2000;14:169-178[CrossRef][Medline] [Order article via Infotrieve]. 9. Gaffney PM, Ortmann WA, Selby SA, et al. Genome screening in human systemic lupus erythematosus: results from a second Minnesota cohort and combined analyses of 187 sib-pair families. Am J Hum Genet. 2000;66:547-556[CrossRef][Medline] [Order article via Infotrieve].
10.
Shai R, Quismorio FP Jr, Li L, et al.
Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families.
Hum Mol Genet.
1999;8:639-644 11. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore). 1976;55:323-339[Medline] [Order article via Infotrieve]. 12. Alger M, Alarcon-Segovia D, Rivero SJ. Hemolytic anemia and thrombocytopenic purpura: two related subsets of systemic lupus erythematosus. J Rheumatol. 1977;4:351-357[Medline] [Order article via Infotrieve]. 13. Miller MH, Urowitz MB, Gladman DD. The significance of thrombocytopenia in systemic lupus erythematosus. Arthritis Rheum. 1983;26:1181-1186[Medline] [Order article via Infotrieve]. 14. Drenkard C, Villa AR, Alarcón-Segovia D, Perez-Vazquez ME. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol. 1994;21:1067-1072[Medline] [Order article via Infotrieve].
15.
Mok CC, Lee KW, Ho CTK, Lau CS, Wong RWS.
A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population.
Rheumatology.
2000;39:399-406 16. Reveille JD, Bartolucci A, Alarcón GS. Prognosis in systemic lupus erythematosus. Arthritis Rheum. 1990;33:37-48[Medline] [Order article via Infotrieve]. 17. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR. Lupus erythematosus in the 1980: a survey of 570 patients. Semin Arthritis Rheum. 1991;21:55-64[CrossRef][Medline] [Order article via Infotrieve]. 18. Abu-Shakra M, Gladman DD, Urowitz MB, Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med. 1995;99:624-628[CrossRef][Medline] [Order article via Infotrieve]. 19. Massardo L, Martinez ME, Jacobelli S, Villarroel L, Rosenberg H, Rivero S. Survival of Chilean patients with systemic lupus erythematosus. Sem Arthritis Rheum. 1994;24:1-11.
20.
Ward MM, Pyun E, Studenski S.
Mortality risks associated with specific clinical manifestations of systemic lupus erythematosus.
Arch Int Med.
1996;156:1337-1344
21.
Swaak AJG, Nossent JC, Bronsveld W, et al.
Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively.
Ann Rheum Dis.
1989;48:447-454 22. Gray-McGuire C, Moser KL, Gaffney P, et al. Genome scan of human systemic lupus erythematosus by regression modeling: evidence of linkage and epistasis at 4p16-15.2. Am J Hum Genet. 2000;67:1460-1469[CrossRef][Medline] [Order article via Infotrieve]. 23. Moser KL, Gray-Mcguire C, Kelly J, et al. Confirmation of genetic linkage between human systemic lupus erythematosus and chromosome 1q41. Arthritis Rheum. 1999;42:1902-1907[CrossRef][Medline] [Order article via Infotrieve]. 24. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725[Medline] [Order article via Infotrieve]. 25. Fritzler MJ. Immunofluorescent antinuclear antibody tests. In: Rose NR,Friedman H,Fahey JL, eds. Manual of Clinical Laboratory Immunology. 3rd ed. Washington, DC: American Society for Microbiology; 1986:733-739.
26.
Clark GM, Reichlin M, Tomasi TB.
Characterization of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythematosus.
J Immunol.
1968;102:117-122 27. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol. 1987;68:215-222[Medline] [Order article via Infotrieve]. 28. Olson JM. Relationship estimation by Markov-process models in a sib-pair linkage study. Am J Hum Genet. 1999;64:1464-1472[Medline] [Order article via Infotrieve]. 29. S.A.G.E. Statistical analysis for genetic epidemiology, release 4.0, Beta 3 (computer package). Cleveland, OH: Department of Epidemiology and Biostatistics, Case Western Reserve University; 1999. 30. Cottingham RW Jr, Idury RM, Schäaffer AA. Faster sequential genetic linkage computations. Am J Hum Genet. 1993;53:252-263[Medline] [Order article via Infotrieve]. 31. Schäffer AA, Gupta SK, Shriram K, Cottingham RW Jr. Avoiding recomputation in linkage analysis. Hum Hered. 1994;44:225-237[Medline] [Order article via Infotrieve]. 32. Terwilliger JD. A powerful likelihood method for the analysis of linkage disequilibrium between trait loci and one or more polymorphic marker loci. Am J Hum Genet. 1995;56:777-787[Medline] [Order article via Infotrieve]. 33. Elston RC, Buxbaum S, Jacobs KB, Olson JM. Haseman and Elston revisited. Genet Epidemiol. 2000;19:1-17[CrossRef][Medline] [Order article via Infotrieve]. 34. Olson JM. A general conditional logistic model for affected-relative-pair linkage studies. Am J Hum Genet. 1999;65:1760-1769[CrossRef][Medline] [Order article via Infotrieve]. 35. Goddard KAB, Witte JS, Suarez BK, Catalona WJ, Olson JM. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4. Am J Hum Genet. 2001;68:1197-1206[CrossRef][Medline] [Order article via Infotrieve]. 36. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet. 1995;11:241-247[CrossRef][Medline] [Order article via Infotrieve]. 37. Kaufman KM, Kelly JA, Harley JB, Scofield RH. A genetic marker within the CD44 gene confirms linkage at 11p13 in African-American families with lupus manifested by thrombocytopenia, but association of CD44 is not present. Gene Immunity. 2002;3(suppl 1):S86-S88. 38. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171-182[CrossRef][Medline] [Order article via Infotrieve]. 39. International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90:797-807[CrossRef][Medline] [Order article via Infotrieve]. 40. Nath SK, Kelly JA, Namjou B, et al. Evidence for a susceptibility gene, SLEV1, on chromosome 17p13 in families with vitiligo-related systemic lupus erythematosus. Am J Hum Genet. 2001;69:1401-1406[CrossRef][Medline] [Order article via Infotrieve].
41.
Kelly JA, Thompson K, Kilpatrick J, et al.
Evidence for a susceptibility gene (SLEH1) on chromosome 11q14 for systemic lupus erythematosus families characterized by hemolytic anemia.
Proc Natl Acad Sci U S A.
2002;99:11766-11771
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M Jeffries, F Hamadeh, T Aberle, S Glenn, D. Kamen, J. Kelly, M Reichlin, J. Harley, and A. Sawalha Haemolytic anaemia in a multi-ethnic cohort of lupus patients: a clinical and serological perspective Lupus, August 1, 2008; 17(8): 739 - 743. [Abstract] [PDF]
|
|
|
|
|
|
K M Eny, A El-Sohemy, M C Cornelis, Y-K Sung, and S-C Bae Catalase and PPARg2 genotype and risk of systemic lupus erythematosus in Koreans Lupus, May 1, 2005; 14(5): 351 - 355. [Abstract] [PDF]
|
|
|
|
|
|
A H Kao, S Manzi, and R Ramsey-Goldman Review of ACR hematologic criteria in systemic lupus erythematosus Lupus, November 1, 2004; 13(11): 865 - 868. [Abstract] [PDF]
|
|
|
|
|
|
J T Merrill Antibodies and clinical features of the antiphospholipid syndrome as criteria for systemic lupus erythematosus Lupus, November 1, 2004; 13(11): 869 - 876. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Prokunina and M. Alarcon-Riquelme The genetic basis of systemic lupus erythematosus--knowledge of today and thoughts for tomorrow Hum. Mol. Genet., April 1, 2004; 13(90001): R143 - 148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Koskenmies, P Lahermo, H Julkunen, V Ollikainen, J Kere, and E Widen Linkage mapping of systemic lupus erythematosus (SLE) in Finnish families multiply affected by SLE J. Med. Genet., January 1, 2004; 41(1): e2 - 5. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
.0007)
3.3).
error is increased. Therefore, we will need to
confirm the present results in another cohort of patients with SLE.